Cedar Investments Limited investment portfolio

1NHALER Ltd develops a propellant‑free, cardboard‑based single‑dose dry‑powder inhaler that folds from a flat credit‑card shape into a three‑dimensional device, using patented membrane dispersion technology to deliver a range of inhalable medicines. The company partners with pharmaceutical organisations and public‑health bodies to provide low‑cost, portable inhalation therapy for conditions such as asthma, epilepsy, allergies and Parkinson’s disease.

Cambridge Oncology Ltd is a biotechnology company developing extracellular‑matrix‑based technologies and therapies aimed at treating glioblastoma. Its focus is on creating novel treatments that inhibit tumour activity in this aggressive brain cancer.